Arecor Therapeutics plc

("Arecor", the "Company" or the "Group")

GRANT OF OPTIONS AND PDMR DEALING

Cambridge, UK, 21 May 2026: Arecor Therapeutics plc (AIM: AREC), a clinical stage biotech company developing superior therapeutics that can reduce treatment burden and improve outcomes for people living with diabetes, obesity and other cardiometabolic diseases, announces that on 20 May 2026 (the "Grant Date") the Company granted a total of 455,000 options under the Company's Long Term Incentive Plan ("LTIP Options") over new ordinary shares of 1 pence each in the Company ("Ordinary Shares").

Details of options granted to PDMRs are included in the table below.

The LTIP Options have an exercise price of 1 pence. Performance conditions include both time (30% of the options granted) and Share Price Outperformance* (70% of the options granted) during the three-year performance period. The LTIP Options are subject to continued service and the extent to which the performance conditions are satisfied. Vesting does not occur until the end of the three-year performance period.  Vested LTIP Options will normally be exercisable from after the end of the three-year performance period and until the tenth anniversary of the Grant Date, after which time they will lapse if not exercised. They are subject to a condition that the LTIP Options or the Ordinary Shares acquired on exercise of the LTIP Options (other than those sold to cover tax and National Insurance) are held for a minimum one-year period from vesting.

*Outperformance when compared to the FTSE AIM All Share index.

The notifications below, made in accordance with the requirements of the Market Abuse Regulation, provide further detail.

-ENDS-

For more information, please contact:

Notes to Editors

Arecor Therapeutics plc is a clinical stage biotech company developing superior therapeutics that can reduce treatment burden and improve outcomes for people living with diabetes, obesity and other cardiometabolic diseases.

Its lead product is AT278, the only ultra-concentrated (500U/mL) ultra-rapid-acting insulin, which enables disruptive drug delivery devices. It is being co-developed with Sequel Med Tech, a company commercialising state-of-the art insulin delivery devices. Arecor is also developing a novel oral delivery platform for peptides with its first validation target a GLP-1 receptor agonist.

The Company is quoted on AIM (AIM: AREC) and is based in Cambridge, UK. For further details please see www.arecor.com

Arecor® and Arestat® are registered trademarks of Arecor Limited.

About AT278

AT278 is a novel proprietary formulation of an existing insulin, designed to accelerate the absorption of insulin post injection even at very high concentrations (500U/mL). With its best-in-class profile, it has the potential to disrupt the market for insulin treatment as the first concentrated, yet very rapid-acting-insulin for the growing population of people with diabetes with high daily insulin needs as well as to act as a critical enabler in the development of next-generation, miniaturised longer wear automated insulin delivery (AID) systems.

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them